Sen. Blumenthal urges AI oversight: 'We're on the verge of losing control'

Senator Richard Blumenthal told CNBC that new AI products should undergo "objective review" before release, but regulation should be targeted and not undermine US competitiveness. He compared the approach to FDA drug regulation and warned that control over AI is nearly lost.

• Blumenthal proposed pre-release review of AI products modeled on FDA
• Regulation should be targeted to not lose advantage over China
• Trump calls fears around AI "a hoax" and "a scam"
• Senator urged not to repeat mistakes with social media and algorithms